Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1H4 | Q96RI1 | 4/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | PTGER4 | P35408 | 2/20 | 0.41 |
| ▸ | PHGDH | O43175 | 1/20 | 0.41 |
| ▸ | PTGER2 | P43116 | 1/20 | 0.41 |
| ▸ | EPHX2 | P34913 | 3/20 | 0.41 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.40 |
| ▸ | PPARD | Q03181 | 1/20 | 0.40 |
| ▸ | TP53 | P04637 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | MMP13 | P45452 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9915325 | 0.92 | SMN1; SMN2 (0.43) | LMNASMN1; SMN2 | |
| SCHEMBL9915520 | 0.86 | NR1H4 (0.45) | NR1H4LMNASMN1; SMN2PTPN11TP53 | |
| SCHEMBL14136527 | 0.84 | PPARD (0.43) | NR1H4LMNASMN1; SMN2PTPN11PPARD | |
| SCHEMBL16747451 | 0.82 | ALDH1A1 (0.40) | LMNATP53TSHR | |
| SCHEMBL14124985 | 0.82 | SGMS2 (0.48) | NR1H4LMNASMN1; SMN2PHGDHEPHX2 | |
| SCHEMBL9915302 | 0.80 | TP53 (0.40) | PTPN11TP53TSHR | |
| SCHEMBL9915331 | 0.78 | MEN1 (0.40) | LMNATSHR | |
| SCHEMBL14136603 | 0.77 | USP2 (0.45) | NR1H4SMN1; SMN2PTPN11PPARD | |
| SCHEMBL16747452 | 0.76 | PTPRC (0.36) | — | |
| SCHEMBL16748804 | 0.76 | NR1H4 (0.46) | NR1H4LMNASMN1; SMN2PTGER4PTGER2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150148326-A1 | Monobactams | PFIZER (US) | 2015-05-28 | — | — | US | disclosed |
| US-20130252935-A1 | Monobactams | PFIZER INC. (US) | 2013-09-26 | — | — | US | disclosed |
| US-20120302542-A1 | MONOBACTAMS | PFIZER INC | 2012-11-29 | — | — | US | disclosed |
| WO-2012073138-A1 | MONOBACTAMS | PFIZER INC. (US) | 2012-06-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130252935-A1 | Monobactams | MGAM, MGAM2, BPGM | NR1H4 277/4885LMNA 4489/4885SMN1; SMN2 4574/4885 |
| US-20150148326-A1 | Monobactams | MGAM, MGAM2, BPGM | NR1H4 277/4885LMNA 4489/4885SMN1; SMN2 4574/4885 |
| US-20120302542-A1 | MONOBACTAMS | MGAM, MGAM2, BPGM | NR1H4 277/4885LMNA 4489/4885SMN1; SMN2 4574/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.